Table 2.
Treatment regimens and patient-reported and objectively measured asthma medication adherence in 178 patients attending a university hospital outpatient clinic
| Treatment and Adherence | N (%), Mean (SD) |
|---|---|
| ICS Prescribed Dose | |
| Low Dose | 66 (37.1%) |
| Moderate Dose | 71 (39.9%) |
| High Dose | 41 (23.0%) |
| Dual ICS Therapy | 32 (18.0%) |
| GINA 2020 Step | |
| Step 2 | 15 (8.4%) |
| Step 3 | 60 (33.7%) |
| Step 4 | 62 (34.8%) |
| Step 5 | 41 (23.0%) |
| Biologic Therapy | 3 (1.7%) |
| Maintenance Oral Corticosteroids | 6 (3.4%) |
| Annual SABA Use (Doses) | 255 (445) |
| of which > 600 doses/yr | 32 (18.0%) |
| Foster Score | 94.0% (19.0%) |
| of which 100% | 156 (87.6%) |
| Inhaled Corticosteroid MPR | 0.54 (0.25) |
| Once-daily ICS MPR (n = 19) | 67.0% (13.1%) |
| Twice-daily ICS MPR (n = 127) | 53.4% (25.2%, p = 0.05*) |
| Dual ICS MPR (n = 32) | 43.9% (26.0%, p = 0.02*) |
| ICS Adherence | |
| 80% or above | 30 (16.9%) |
| Below 80% | 148 (83.1%) |
* Versus patients receiving once-daily ICS. N number of patients, IQR inter-quartile range, ICS Inhaled Corticosteroids, GINA Global Initiative for Asthma (2020), MPR medication possession ratio, LABA long-acting β2-agonist, LAMA long-acting muscarinic receptor antagonist, SABA short-acting β2-agonist, MPR medication possession ratio, SD standard deviation